Wednesday, April 30, 2014

Published Reports: UK's Reckitt Is. . . Out. Consumer Health Indicated Deal Numbers MAY Be Over-Heated. [Just As I Said.]


So, it is now reputedly down to Bayer AG and maybe P&G and a few others. Reckitts (the plural is the British way of referring to it, BTW) has pushed away from the table, we are told.

But just as I said -- IF the rumored numbers are remotely-accurate -- Merck would be getting the very tip top of the market. Per LiveMint's reporting -- do go read it all:

. . . .Bayer AG moved a step closer to winning Merck and Co.’s consumer business after lead rival Reckitt Benckiser Group Plc walked away from the deal because the asset became too expensive.

“We are a highly disciplined acquirer with strict return metrics, which we will not break,” Reckitt Benckiser chief executive officer (CEO) Rakesh Kapoor said in an e-mailed statement. . . .


We shall -- as ever -- see.

3 comments:

Anonymous said...

Consumer is not the only thing on the block. Legacy drugs are being shopped around as the salesforce is being ramped down dramatically in July.

http://in.mobile.reuters.com/article/idINBREA3T10M20140430?irpc=932

Condor said...

Quite right!

A whole new batch of largely mindless rumors, very likely floated by bankers retained by Merck to maximize the price.

Here's a new post -- with my commentary, in the waning paragraph of this one -- on it. @X to @.%X annual sales I probably about all we should expect -- in pricing, on sale. . . .

Namaste -- and do stop back!

Condor said...

Wow.

That should read 2X to 2.5X. . .

Sorry -- going to get some real coffee now.

Namaste!